Skip to main content

CorMedix Inc 10-Q for FY2026 Q3

CorMedix Inc. (CRMD)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

CorMedix Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

CorMedix agreed to acquire substantially all of Heron Therapeutics’ assets, adding four commercial-stage products—ZYNRELEF, APONVIE, CINVANTI and SUSTOL—for $145.0 million cash and 14,583,333 shares. Closing is expected in the first quarter of 2027. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$54.52M
down 47.7% from $104.28M a year earlier
Net loss
$14.72M
compared with net income of $108.56M a year earlier
Diluted EPS
-$0.19
compared with $1.26 a year earlier